Skip to main content
Equibles

Candriam S.C.A.

Position in SYRE — Spyre Therapeutics, Inc.

CIK 1537014 STRASSEN, N4
Back to SYRE Full portfolio

Position in SYRE

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$48,501,579
+$17,718,955 QoQ
Shares Held
546,312
-10.5% QoQ
Ownership
0.620%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
#39
of 266 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SYRE Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Candriam S.C.A. holds $2,107,868,027 across 75 Biotechnology names. SYRE ranks #11 (2.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 REGN
Regeneron Pharmaceuticals, Inc.
 195,674 $122,010,565
2 RVMD
Revolution Medicines, Inc.
 556,392 $104,201,093
3 VRTX
Vertex Pharmaceuticals Inc / Ma
 199,505 $99,100,118
4 ALNY
Alnylam Pharmaceuticals, Inc.
 314,512 $94,677,547
5 ONC
BeOne Medicines Ltd.
 289,735 $82,565,782
6 COGT
Cogent Biosciences, Inc.
 2,088,369 $80,819,880
7 ARGX
Argenx SE
 80,120 $74,332,932
8 ROIV
Roivant Sciences Ltd.
 1,990,510 $70,444,148

All Filings in SYRE

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $48,501,579 546,312
2026-03-31 $30,782,624 610,282
2025-12-31 $13,940,493 425,534
2025-09-30 $6,777,107 404,362
2025-06-30 $3,683,069 246,030
2025-03-31 $3,969,694 246,030
2024-12-31 $5,763,918 247,591
2024-09-30 $3,088,050 105,000
2024-06-30 $2,468,550 105,000
2024-03-31 $3,982,650 105,000